Blue Star Opportunities AI solutions can help protect from widespread prescription errors.
Since 1999 no progress in reduction of deadly medication errors
RENO, NV, May 15th, 2024. Blue Star Opportunities Corp. (The "Company") (OTC: BSTO),announces that the need for its Diomedes MedGuard AI system for personal medication safety is supported by recent actions from The National Institute of Health as the institution continues to focus the attention of the medical community on the continuing prevalence of medical errors in the American healthcare system.(See NIH website or https://pubmed.ncbi.nlm.nih.gov/30085607/). The Institute continues to promote special education programs regarding adverse drugs events which it first reported broadly as a major public health issue back in 1999. There seems to have been no progress since then in reducing medication errors since the numbers have remain constant.
“ Medical errors are a serious public health problem and a leading cause of death in the United States. It is challenging to uncover a consistent cause of errors and, even if found, to provide a consistent viable solution that minimizes the chances of a recurrent event. ” quotes the NIH website.
Our Diomedes MedGuard technology was first developed at the McGill University Health System many years ago but with new AI apps will now be made available directly to consumers who wish to protect themselves from the Adverse Drug Events reported by the NIH.
“ People concerned about their health need to take charge in their own hands” said clinical director Stella Papadoukakis, “ and need to understand the extent to which the health system is failing so many patients.”
Our Diomedes MedGuard system is available as an app; a simple scan of any medication on your phone will trigger an approval, a warning or a recommendation to go back to your doctor for further investigation. Not all drugs fit everyone; variations include the dosage, possible interaction and various levels of allergies which may not always be taken into consideration. Often there is a lack of continuity from test to diagnostic to prescription to actual issuance of the medications by the drug store.
The Company sees the current conditions as a critical support for its AI safety offerings to individuals and families and its other lines of science-based natural prophylactic healthcare products.
About Blue Star Opportunities Corp
Blue Star Opportunities Corp, an AI clinical analytics company, is expanding operations in the field of AI driven innovative solutions to help consumers better manage health and safety issues. The Company also provides advanced and innovative solutions to enhance the consumer’s immune systems. These are breakthrough innovative solutions that offer a better opportunity for growth and building shareholder value. More information and details on our performance can be found in our filings with OTCMarkets.com.
FORWARD-LOOKING STATEMENTS: Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of the Company. These statements are based on suppositions and uncertainties as well as on management best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Company products and services, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.
Media Contact: Michel Dab 438-501-6500